Hsbc Holdings PLC Uni Qure N.V. Transaction History

Hsbc Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $202,092 - $304,699	11,153 New	11,153 $252,000
Q2 2022 Aug 11, 2022	BUY	$13.15 - $20.45 $6,522 - $10,143	496 Added 4.63%	11,201 $208,000
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $155,650 - $230,157	10,705 New	10,705 $192,000
Q2 2021 Aug 13, 2021	SELL	$29.97 - $37.17 $273,895 - $339,696	-9,139 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$29.24 - $42.03 $267,224 - $384,112	9,139 New	9,139 $307,000
Q3 2020 Nov 12, 2020	SELL	$35.98 - $47.66 $263,013 - $348,394	-7,310 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $70,383 - $105,809	1,562 Added 27.17%	7,310 $329,000
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $229,977 - $425,179	5,748 New	5,748 $273,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.